Wine Consumption Linked to Increased Survival Rates in non-Hodgkin's Lymphoma

According to a study presented at the recent American Association for Cancer Research, a pre-diagnostic lifestyle that includes drinking wine may help save the lives of some patients suffering from non-Hodgkin's lymphoma.

The study looked at over 540 women with non-Hodgkin's lymphoma and discovered that those who drank wine had an increased five-year survival percentage over the women who didn't drink wine (76% compared to 68%). In addition, five-year, disease-free survival was higher for wine drinkers as well (70% compared to 65%).

The authors of the study, which included a doctoral candidate at the Yale School of Public Health, are urging caution, stressing that the results of this study by no means amounted to a public health recommendation. They said that the evidence favors drinking wine in moderation for a number of health benefits, but until a reliable and widely applicable definition of "in moderation" exists, the conclusion remains a controversial one.

One more thing: the increased survival rates applied to wine drinkers only. Niether beer nor liquor had the same effect.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap